NCT05233397 2026-04-08
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Phase 2 Recruiting
Clinical Trials
19 trialsNCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05972135 2026-02-23
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT04375228 2026-02-06
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
Phase 2 Active not recruiting
NCT05846789 2026-01-21
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Indiana University
Phase 2 Recruiting
NCT06043674 2026-01-07
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04377659 2025-05-28
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT03821246 2025-05-15
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
University of California, San Francisco
Phase 2 Recruiting
NCT03434730 2025-04-22
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03708224 2025-01-28
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of California, San Francisco
Phase 2 Recruiting
NCT02385110 2024-01-17
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05833763 2024-01-08
GOlDiLOX
Australasian Leukaemia and Lymphoma Group
Phase 2 Recruiting
NCT02767557 2023-09-22
PACTO
Herlev Hospital
Phase 2 Completed
NCT03699631 2023-04-19
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Medical College of Wisconsin
Phase 2 Completed
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT04871854 2022-11-01
Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
Beni-Suef University
Phase 2 Completed
NCT04258150 2022-03-31
TRIPPLE-R
Herlev Hospital
Phase 2 Terminated